Belite Bio Statistics
Total Valuation
Belite Bio has a market cap or net worth of $2.08 billion. The enterprise value is $1.93 billion.
Market Cap | 2.08B |
Enterprise Value | 1.93B |
Important Dates
The last earnings date was Tuesday, May 13, 2025, after market close.
Earnings Date | May 13, 2025 |
Ex-Dividend Date | n/a |
Share Statistics
Belite Bio has 32.28 million shares outstanding. The number of shares has increased by 8.22% in one year.
Current Share Class | n/a |
Shares Outstanding | 32.28M |
Shares Change (YoY) | +8.22% |
Shares Change (QoQ) | +1.98% |
Owned by Insiders (%) | 1.41% |
Owned by Institutions (%) | 0.69% |
Float | 14.73M |
Valuation Ratios
PE Ratio | n/a |
Forward PE | n/a |
PS Ratio | n/a |
Forward PS | n/a |
PB Ratio | 13.07 |
P/TBV Ratio | 13.15 |
P/FCF Ratio | n/a |
P/OCF Ratio | n/a |
PEG Ratio | n/a |
Enterprise Valuation
EV / Earnings | n/a |
EV / Sales | n/a |
EV / EBITDA | n/a |
EV / EBIT | n/a |
EV / FCF | n/a |
Financial Position
The company has a current ratio of 25.98
Current Ratio | 25.98 |
Quick Ratio | n/a |
Debt / Equity | n/a |
Debt / EBITDA | n/a |
Debt / FCF | n/a |
Interest Coverage | -2,359.25 |
Financial Efficiency
Return on equity (ROE) is -33.43% and return on invested capital (ROIC) is -23.17%.
Return on Equity (ROE) | -33.43% |
Return on Assets (ROA) | -22.23% |
Return on Invested Capital (ROIC) | -23.17% |
Return on Capital Employed (ROCE) | -29.85% |
Revenue Per Employee | n/a |
Profits Per Employee | -$1.70M |
Employee Count | 25 |
Asset Turnover | n/a |
Inventory Turnover | n/a |
Taxes
Income Tax | n/a |
Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +53.12% in the last 52 weeks. The beta is -1.48, so Belite Bio's price volatility has been lower than the market average.
Beta (5Y) | -1.48 |
52-Week Price Change | +53.12% |
50-Day Moving Average | 62.48 |
200-Day Moving Average | 59.51 |
Relative Strength Index (RSI) | 57.58 |
Average Volume (20 Days) | 24,999 |
Short Selling Information
Short Interest | 72,906 |
Short Previous Month | 60,691 |
Short % of Shares Out | 0.49% |
Short % of Float | n/a |
Short Ratio (days to cover) | 1.94 |
Income Statement
Revenue | n/a |
Gross Profit | n/a |
Operating Income | -47.19M |
Pretax Income | -31.62M |
Net Income | -42.55M |
EBITDA | -47.01M |
EBIT | -47.19M |
Earnings Per Share (EPS) | -$1.37 |
Balance Sheet
Cash & Cash Equivalents | n/a |
Total Debt | n/a |
Net Cash | n/a |
Net Cash Per Share | n/a |
Equity (Book Value) | 158.07M |
Book Value Per Share | 4.93 |
Working Capital | 153.16M |
Cash Flow
Operating Cash Flow | n/a |
Capital Expenditures | n/a |
Free Cash Flow | n/a |
FCF Per Share | n/a |
Margins
Gross Margin | n/a |
Operating Margin | n/a |
Pretax Margin | n/a |
Profit Margin | n/a |
EBITDA Margin | n/a |
EBIT Margin | n/a |
FCF Margin | n/a |
Dividends & Yields
Belite Bio does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Years of Dividend Growth | n/a |
Payout Ratio | n/a |
Buyback Yield | -8.22% |
Shareholder Yield | n/a |
Earnings Yield | -2.05% |
FCF Yield | n/a |
Analyst Forecast
The average price target for Belite Bio is $96.67, which is 48.72% higher than the current price. The consensus rating is "Strong Buy".
Price Target | $96.67 |
Price Target Difference | 48.72% |
Analyst Consensus | Strong Buy |
Analyst Count | 4 |
Revenue Growth Forecast (5Y) | n/a |
EPS Growth Forecast (5Y) | n/a |
Stock Splits
This stock does not have any record of stock splits.
Last Split Date | n/a |
Split Type | n/a |
Split Ratio | n/a |
Scores
Altman Z-Score | n/a |
Piotroski F-Score | 1 |